2 weeks ago

Molbio Diagnostics IPO Monday debut; GMP, experts signal gains

Molbio Diagnostics IPO Monday debut; GMP, experts signal gains
Molbio Diagnostics IPO listing date tomorrow. Here's what GMP, experts signal ahead of debut · livemint.com

Molbio Diagnostics is a company that makes quick medical tests to find out if people are sick.

The company sold a part of itself to the public in a process called an IPO, so many people can own a tiny piece of it.

The offer was very popular — people wanted 70 times more shares than were available.

On Monday, 17 August, these shares will start selling on two big Indian stock markets for the first time.

Before the stock market opens, people who guess share prices think the shares could be worth about ₹932, which is more than the ₹807 that buyers paid.

Experts think the shares may jump 14 to 16 percent on the first day.

The money from the sale will be used to build a research lab, buy machines, and help the company grow in places like Goa and Visakhapatnam.

Some experts say people who plan to keep the shares for years should hold on to them, while others say quick traders might take some profit on the first day.

The company's earnings have grown from about ₹836 crore to ₹1,445 crore in a few years.

Key facts

Listing date
Monday, 17 August
Exchanges
NSE and BSE
Overall subscription
70.26 times (QIBs 186.39x, NIIs 49.80x, retail 12.96x)
Issue price
₹807 (price band ₹768–₹807)
Grey market premium
₹125 (implied listing price ₹932, ~15.49% premium)
Fresh issue / OFS
₹200 crore fresh issue; OFS of 91.66 lakh shares worth ₹739.70 crore
Revenue from operations
₹836.56 crore (FY24), ₹1,020.42 crore (FY25), ₹1,445.69 crore (FY26)

Quotes

Harshal Dasani

Business Head – INVasset PMS

“"The market will increasingly focus on whether Molbio can sustain its growth, deepen recurring test‑kit revenues, scale its international business and convert R&D into commercially successful products. For us, this is a credible diagnostics franchise, but the durability of returns from here will depend far more on earnings delivery than on listing‑day momentum."”
livemint.com
“"However, considering the elevated IPO valuation, short‑term investors may consider booking partial gains if the stock delivers the expected 14–16% listing gain. Fresh investors are advised to wait for post‑listing price stabilization and valuation comfort before taking a fresh position."”
livemint.com

Sources

Related news